• HOME»
  • »
  • Misleading Ads Case: Baba Ramdev And Acharya Balkrishan Reach at SC

Misleading Ads Case: Baba Ramdev And Acharya Balkrishan Reach at SC

Yog guru Baba Ramdev and Patanjali Ayurved CMD Acharya Balkrishan arrived at the Supreme Court to attend the hearing relating to misleading advertisements by Patanjali Ayurved. Earlier, the licensing authority in Uttarakhand has reportedly suspended the manufacturing permits for 14 products produced by Baba Ramdev’s Patanjali’s Divya Pharmacy due to the repeated dissemination of misleading […]

Advertisement
Misleading Ads Case: Baba Ramdev And Acharya Balkrishan Reach at SC

Yog guru Baba Ramdev and Patanjali Ayurved CMD Acharya Balkrishan arrived at the Supreme Court to attend the hearing relating to misleading advertisements by Patanjali Ayurved.

Earlier, the licensing authority in Uttarakhand has reportedly suspended the manufacturing permits for 14 products produced by Baba Ramdev’s Patanjali’s Divya Pharmacy due to the repeated dissemination of misleading advertisements regarding their effectiveness.

Additionally, a criminal complaint has allegedly been lodged against Ramdev, Acharya Balkrishna, and Patanjali for breaching the Drugs and Magic Remedies Act.

The case against Ramdev in the Supreme Court stems from allegations by the Indian Medical Association that his company, Patanjali Ayurved, disparages conventional medicines and continues to publish misleading ads despite a court order to cease.

Ramdev has acknowledged his wrongdoing and his company has issued newspaper advertisements apologizing to the public. In recent weeks, he has appeared before the judges of the Supreme Court clad in his signature saffron-colored robe, seeking forgiveness. However, the judges have thus far not accepted his apology, and they are deliberating whether to pursue contempt charges against Ramdev.

In that order, the court noted assurances from counsel representing Patanjali Ayurved that there would be no further violations of laws, particularly regarding advertising or branding, and no release of casual statements claiming medicinal efficacy or against any system of medicine.

Advertisement